Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction

Neoplasia

Volumn 10, Issue 11, 2008, Pages 1268-1274

  Chesler, Louis ^a,b,c   Goldenberg, David D ^a   Collins, Rodney ^a   Grimmer, Matt ^a   Kim, Grace E ^a   Tihan, Tarik ^a   Nguyen, Kim ^a   Yakovenko, Slava ^a   Matthay, Katherine K ^a   Weiss, William A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CASPASE 3; CASPASE 9; CYCLOPHOSPHAMIDE; MYCN PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN DERIVATIVE; PROTEIN P53; PUMA PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLOGY; CANCER CHEMOTHERAPY; CARCINOGENESIS; CHILDHOOD; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; MUTATION; NEUROBLASTOMA; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INDUCTION; RELAPSE; TRANSGENIC MOUSE; TREATMENT RESPONSE; TUMOR CELL LINE; TUMOR REGRESSION; WILD TYPE;

EID: 55849138371     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08778     Document Type: Article

References (34)

1. Maris JM and Matthay KK (1999). Molecular biology of neuroblastoma. J Clin Oncol 17, 2264-2279.
2. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, et al. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341, 1165-1173.
3. Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Perez C, Haase GM, and Matthay KK (2000). Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group Study. J Clin Oncol 18, 1260-1268.
4. Brodeur GM, Seeger RC, Schwab M, Varmus HE, and Bishop JM (1985). Amplification of N-myc sequences in primary human neuroblastomas: correlation with advanced disease stage. Prog Clin Biol Res 175, 105-113.
5. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, and Hammond D (1985). Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313, 1111-1116.
6. Fulda S, Lutz W, Schwab M, and Debatin KM (1999). MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 18, 1479-1486.
7. van Noesel MM, Pieters R, Voute PA, and Versteeg R (2003). The N-myc paradox: N-myc overexpression in neuroblastomas is associated with sensitivity as well as resistance to apoptosis. Cancer Lett 197, 165-172.
8. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, and Schwab M (1996). Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13, 803-812.
9. Keshelava N, Seeger RC, and Reynolds CP (1997). Drug resistance in human neuroblastoma cell lines correlates with clinical therapy. Eur J Cancer 33, 2002-2006.
10. Keshelava N, Seeger RC, Groshen S, and Reynolds CP (1998). Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58, 5396-5405.
11. Carr J, Bell E, Pearson AD, Kees UR, Beris H, Lunec J, and Tweddle DA (2006). Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res 66, 2138-2145.
12. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, and Lunec J (2001). Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 61, 8-13.
13. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, et al. (2000). High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19, 617-623.
14. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ikegaki N, and Brodeur GM (2000). Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Med Pediatr Oncol 35, 603-607.
15. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, and Kidd VJ (2000). Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6, 529-535.
16. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, and Nunez G (1993). Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol 143, 1543-1550.
17. Mora J, Cheung NK, and Gerald WL (2001). Genetic heterogeneity and clonal evolution in neuroblastoma. Br J Cancer 85, 182-189.
18. Teitz T, Lahti JM, and Kidd VJ (2001). Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death. J Mol Med 79, 428-436.
19. Norris MD, Bordow SB, Haber PS, Marshall GM, Kavallaris M, Madafiglio J, Cohn SL, Salwen H, Schmidt ML, Hipfner DR, et al. (1997). Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma. Eur J Cancer 33, 1911-1916.
20. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, and Bishop JM (1997). Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16, 2985-2995.
21. Norris MD, Burkhart CA, Marshall GM, Weiss WA, and Haber M (2000). Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model. Med Pediatr Oncol 35, 585-589.
22. Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, Hogarty MH, Sulman EP, Thompson PM, Lukens JN, et al. (2000). Loss of heterozygosity at 1p36 independently predicts for disease progression, but not decreased overall survival probability, in neuroblastoma patients: a Children's Cancer Group Study. J Clin Oncol 18, 1888-1899.
23. Keshelava N, Zuo JJ, Waidyaratne NS, Triche TJ, and Reynolds CP (2000). p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med Pediatr Oncol 35, 563-568.
24. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, and Reynolds CP (2001). Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 61, 6185-6193.
25. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, and Bradley A (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221.
26. Momota H and Holland EC (2005). Bioluminescence technology for imaging cell proliferation. Curr Opin Biotechnol 16, 681-686.
27. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, et al. (2003). Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4, 321-328.
28. Fulda S, Lutz W, Schwab M, and Debatin KM (2000). MycN sensitizes neuroblastoma cells for drug-triggered apoptosis. Med Pediatr Oncol 35, 582-584.
29. Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C, and Pleasure D (1991). Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 51, 6529-6538.
30. Dansen F, Whitfield J, Rostker F, Brown-Swigart L, and Evan G (2006). Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivo. J Biol Chem 281, 10890-10895.
31. Hemann MT, Zilfou JT, Zhao Z, Burgess DJ, Hannon GJ, and Lowe SW (2004). Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci USA 101, 9333-9338.
32. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, and Green DR (2005). PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309, 1732-1735.
33. Xue C, Haber M, Flemming C, Marshall GM, Lock RB, Mackenzie KL, Gurova KV, Norris MD, and Gudkov AV (2007). p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res 67, 10351-10360.
34. Armstrong MB, Bian X, Liu Y, Subramanian C, Ratanaproeksa AB, Shao F, Yu VC, Kwok RP, Opipari AW, and Castle VP (2006 Nov). Signaling from p53 to NF-kappa B determines the chemotherapy responsiveness of neuroblastoma. Neoplasia 8 (11), 964-974.